Victoria Socha

DocwireNews

Results of previous studies have shown that tolvaptan slows expansion of kidney volume and decline in kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). According to Djalila Mekahli, MD, PhD, and colleagues, there are few data available on the efficacy and safety of treatment with tolvaptan in children and adolescents with ADPKD.
The researchers reported results of a 1-year, randomized, double-blind portion of a phase 3b two-part trial being conducted at 20 academic pediatric nephrology centers [Clinical Journal of the American Society of Nephrology. 2023;18(1):36-46].
Eligibility criteria included ADPKD and estimated glomerular filtration rate ≥60 mL/min/1.73 m2. The target group was patients 12 to 17 years of age (group 1, enrollment goal &gt;60); patients 4 to 11 years of age could additionally enroll (group 2, anticipated enrollment approximately 40).
Participants received either <a href="https://www.docwirenews.com/nephtimes/nephtimes-diseases-and-conditions/adpkd/tolvaptan-long-term-safety-in-patients-with-adpkd/">tolvaptan</a> or placebo titrated by body weight and tolerability. The primary end points of interest were change from baseline in spot urine osmolality and specific gravity at week 1, and assessed inhibition of antidiuretic hormone activity. Secondary end points included change in height-adjusted total kidney volume (htTKV) to month 12 in group 1, safety and tolerability, and quality of life. Statistical comparisons were exploratory and post hoc.
The total cohort included 91 participants; of those, 66 were in group 1 and 25 were in group 2. Least squares mean reduction in spot urine osmolality at week 1 was greater with tolvaptan than placenbo (–390 mOsm/kg vs –90 mOsm/kg, respectively; P&lt;.001). Least squares mean reduction in specific gravity was also greater with tolvaptan than with placebo (–0.009 vs –0.002, respectively; P&lt;.001).
In group 1, the 12-month increase in htTKV was 2.6% with tolvaptan and 5.8% with placebo (P&lt;.05). In the tolvaptan group, 65% experienced aquaretic adverse events and 2% experienced hypernatremia. The corresponding percentages in the placebo group were 16% and 0%. There were no elevated transaminases or drug-induced liver injuries in either group. Four participants in the tolvaptan group discontinued the study drug and three in the placebo group discontinued placebo. Assessments of quality-of-life remained stable in both groups.
In summary, the authors said, “Tolvaptan exhibited pharmacodynamic activity in pediatric ADPKD. Aquaretic effects were manageable, with few discontinuations.”
Clinical Trial registry and registration number: Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children with Adolescents with ADPKD (Autosomal Dominant Polycystic Kidney Disease). NCT02964273.

Cecilia Brown

CHRYSALIS-2 Study Evaluates Amivantamab Plus Lazertinib in Population With Limited Treatment Options for NSCLC

EGFR+ NSCLC

Rob Dillard

Artificial Intelligence–based Model Successful at Predicting Hypertension

Hypertension

Laura Litwin

Disparities in Gastric Cancer Screening Contribute to Rising Global Burden of the Disease

Gastric Cancer

Latest News

Tolvaptan for Pediatric ADPKD

Nephrology Times

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe